Cipla Receives Final Approval for Generic Reyataz® (Atazanavir Caps 100 mg, 150 mg, 200 mg, 300 mg)

Cipla Limited (Cipla) today announced that it has received final approval for its Abbreviated New Drug Application (ANDA) for Atazanavir Caps 100 mg, 150 mg, 200 mg, 300 mg from the United States Food and Drug Administration (US FDA). Cipla’s Atazanavir Caps 100 mg, 150 mg, 200 mg, 300 mg are AB-rated generic therapeutic equivalent versions of Bristol-Myers Squibb Pharma Company’s, Reyataz®. It is a protease inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in patients with minimum age of 6 years and older weighing at least 15 kg. According to IQVIA (IMS Health), Reyataz® and its generic equivalents had US sales of approximately USD 324 million for the 12-month period ending April 2018.-Medical Buyer Bureau